XTL Biopharmaceuticals Ltd.
113.4M
$1.21M
-3.33
$-2.44
No price alerts set. Add an alert to get notified!
-3.33
0.63
$-2.44
-18.90%
-227.72%
-481.60%
Compare TSM with similar companies in the sector
| Company | Price | Change % | P/E | Market Cap | D/E |
|---|---|---|---|---|---|
|
AIM
AIM ImmunoTech Inc.
|
$0.52 | 0.83% | -0.12 | $1.78M | -0.50 |
|
CYCN
Cyclerion Therapeutics, Inc.
|
$3.32 | 9.21% | -3.03 | $14.38M | 0.00 |
|
ENSC
Ensysce Biosciences, Inc.
|
$0.36 | -5.64% | -0.09 | $3.35M | 95,437.06 |
|
KALA
KALA BIO, Inc.
|
$0.11 | -4.45% | -0.03 | $2.40M | 0.00 |
|
KTTA
Pasithea Therapeutics Corp.
|
$0.69 | 2.17% | -0.24 | $5.13M | 0.00 |
|
PLRZ
Polyrizon Ltd.
|
$15.72 | -4.73% | -6.14 | $17.61M | 0.00 |
|
QNRX
Quoin Pharmaceuticals, Ltd.
|
$5.93 | 8.81% | 0.00 | $3.49M | 0.00 |
|
RADX
Radiopharm Theranostics Limited
|
$4.35 | -0.68% | -1.10 | $5.60M | 0.00 |
|
TCRT
Alaunos Therapeutics, Inc.
|
$2.56 | -1.16% | -1.19 | $6.09M | 0.00 |
|
VYNE
VYNE Therapeutics Inc.
|
$0.64 | -0.63% | -1.03 | $10.60M | 0.00 |
* Peer stocks are selected based on market capitalization and sector
$10.28
$2.12
$0.00
0.00%
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
